Vathiotis, Ioannis A. http://orcid.org/0000-0002-1772-5986
Salichos, Leonidas
Martinez-Morilla, Sandra
Gavrielatou, Niki
Aung, Thazin Nwe http://orcid.org/0000-0003-4150-0426
Shafi, Saba
Wong, Pok Fai
Jessel, Shlomit
Kluger, Harriet M.
Syrigos, Konstantinos N.
Warren, Sarah
Gerstein, Mark http://orcid.org/0000-0002-9746-3719
Rimm, David L. http://orcid.org/0000-0001-5820-4397
Article History
Received: 24 May 2022
Accepted: 3 November 2022
First Online: 15 December 2022
Competing interests
: H.M.K. reports grants and personal fees from Merck and Bristol-Myers, Squibb, grants from Apexigen, personal fees from Iovance, Immunocore, Celldex, Array BioPharma, Elevate Bio, Instil Bio, Clinigen, Shionogi, and Chemocentryx, outside the submitted work. S.W. is an employee of NanoString Technologies. D.L.R. has served as an advisor for Astra Zeneca, Agendia, Amgen, BMS, Cell Signaling Technology, Cepheid, Daiichi Sankyo, Genoptix/Novartis, GSK, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Ventana and Ultivue, and received research funding from Astra Zeneca, Cepheid, NavigateBP, NextCure, Nanostring, Lilly and Ultivue. The other authors declare no potential conflicts of interest.